Edge Therapeutics Company Profile (NASDAQ:EDGE)

About Edge Therapeutics

Edge Therapeutics, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions. The Company's product candidates include EG-1962 and EG-1964. The Company's lead product candidate, EG-1962, is initially being developed to improve clinical outcomes following subarachnoid hemorrhage (SAH) by administration through an external ventricular drain (EVD). Its second product candidate, EG-1964, contains aprotinin, a pancreatic trypsin inhibitor initially marketed as Trasylol, and is being developed using its Precisa development platform for the management of chronic subdural hematoma (cSDH), as a prophylactic treatment to prevent recurrent bleeding. Its product candidates utilize its Precisa development platform, which allows the Company to create therapeutics that are based on specific physical and chemical properties.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: EDGE
CUSIP:

Key Metrics:

Previous Close: $10.41
50 Day Moving Average: $10.03
200 Day Moving Average: $9.23
52-Week Range: $6.23 - $25.87
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -6.35
P/E Growth: -0.08
Market Cap: $300.83M
Outstanding Shares: 28,898,000

Profitability:

Return on Equity: -49.96%
Return on Assets: -33.94%

Debt:

Debt-to-Equity Ratio: 0.02%
Current Ratio: 16.54%
Quick Ratio: 16.54%

Additional Links:

Companies Related to Edge Therapeutics:

Consensus Ratings for Edge Therapeutics (NASDAQ:EDGE) (?)

Ratings Breakdown:	4 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$22.50 (116.14% upside)

Analysts' Ratings History for Edge Therapeutics (NASDAQ:EDGE)

Show:

Date	Firm	Action	Rating	Price Target
5/9/2016	Credit Suisse Group AG	Lower Price Target	Outperform	$19.00 -> $18.00
3/11/2016	Leerink Swann	Reiterated Rating	Outperform	$27.00 -> $24.00
3/9/2016	JMP Securities	Lower Price Target	Market Outperform	$34.00 -> $18.00
10/26/2015	Guggenheim	Initiated Coverage	Buy	$30.00

(Data available from 10/1/2014 forward)

Earnings History for Edge Therapeutics (NASDAQ:EDGE)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/4/2016
8/3/2016	Q2	($0.38)	($0.33)	View	Listen
5/3/2016		($0.34)	($0.32)	View	Listen
3/8/2016	Q4	($0.32)	($0.30)	View	Listen
11/6/2015	Q315	($0.23)	($7.08)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Edge Therapeutics (NASDAQ:EDGE)

Current Year EPS Consensus Estimate: $-1.43 EPS
Next Year EPS Consensus Estimate: $-1.64 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.42)	($0.42)	($0.42)
Q2 2016	1	($0.43)	($0.43)	($0.43)
Q3 2016	1	($0.38)	($0.38)	($0.38)
Q4 2016	1	($0.41)	($0.41)	($0.41)

(Data provided by Zacks Investment Research)

Dividend History for Edge Therapeutics (NASDAQ:EDGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Edge Therapeutics (NASDAQ:EDGE)

Insider Ownership Percentage: 44.29%
Institutional Ownership Percentage: 47.94%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/8/2016	W Bradford Middlekauff	VP	Buy	10,000	$9.48	$94,800.00
8/1/2016	Brian A Leuthner	Insider	Sell	7,500	$9.54	$71,550.00
3/11/2016	James Healy	Director	Buy	541,343	$7.30	$3,951,803.90
10/6/2015	Andrew J. Einhorn	CFO	Buy	45,000	$11.00	$495,000.00
10/6/2015	James Healy	Director	Buy	450,000	$11.00	$4,950,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Edge Therapeutics (NASDAQ:EDGE)

Date	Headline
	The first report delivered on Sage Therapeutics, Inc. - 2016 Product Pipeline ... (NASDAQ:EDGE) www.medgadget.com - September 30 at 9:50 AM
	What Analysts are saying about? Deutsche Bank AG (NYSE:DB) , Edge Therapeutics, Inc. (NASDAQ:EDGE) - Wall Street Times (press release) (NASDAQ:EDGE) www.wallstreetnews24.com - September 29 at 4:43 PM
	Broker Roundup For Edge Therapeutics, Inc. (NASDAQ:EDGE) - The De Soto Edge (NASDAQ:EDGE) desotoedge.com - September 29 at 4:43 PM
	Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Updated Broker Price Targets (NASDAQ:EDGE) desotoedge.com - September 29 at 9:46 AM
	New Analyst Ratings On Edge Therapeutics, Inc. (NASDAQ:EDGE) - NewsDen (NASDAQ:EDGE) newsden.net - September 28 at 4:38 PM
	Fortis Therapeutics Closes $18 Million Series A Financing to Advance New Antibody Drug Conjugate Therapies for the Treatment of Late-Stage Cancers (NASDAQ:EDGE) www.medindia.net - September 27 at 9:22 AM
	Mover to Watch: Edge Therapeutics, Inc. (NASDAQ:EDGE) , Pacific DataVision, Inc. (NASDAQ:PDVW) - Wall Street Times (press release) (NASDAQ:EDGE) www.wallstreetnews24.com - September 21 at 5:18 PM
	Edge Therapeutics Incorporated (NASDAQ:EDGE) Short Interest Increased By 1.71% - Post News (NASDAQ:EDGE) www.kentuckypostnews.com - September 19 at 3:38 PM
	Edge Therapeutics : Announces Closing of $20 Million Debt Facility with Hercules Capital, Inc. (NASDAQ:EDGE) www.4-traders.com - September 16 at 4:38 PM
	Ember Therapeutics Acquires Dermasilk™ Brands (NASDAQ:EDGE) finance.yahoo.com - September 12 at 4:35 PM
	Sizzling Stocks Alerts - Exar Corporation (NYSE:EXAR) , Edge Therapeutics, Inc. (NASDAQ:EDGE) - Wall Street Times (press release) (NASDAQ:EDGE) www.wallstreetnews24.com - September 12 at 9:39 AM
	Edge Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series and ... - GlobeNewswire (press release) (NASDAQ:EDGE) globenewswire.com - September 10 at 4:29 PM
	Edge Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series and Participate in Additional Investor… (NASDAQ:EDGE) forextv.com - September 8 at 4:40 PM
	Edge Therapeutics Announces Additional Pharmacokinetic Data Supporting The Potential Clinical And Health ... - Clinical Leader (NASDAQ:EDGE) www.clinicalleader.com - September 8 at 8:35 AM
	Edge Therapeutics to Present at the Leerink Partners Rare Disease Immuno-Oncology Roundtable Series and ... - EconoTimes (NASDAQ:EDGE) www.econotimes.com - September 8 at 8:35 AM
	Edge Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series and Participate in Additional Investor Conferences in September (NASDAQ:EDGE) www.publicnow.com - September 8 at 8:35 AM
	Edge Therapeutics Announces Additional Pharmacokinetic Data ... - EconoTimes (NASDAQ:EDGE) www.econotimes.com - September 7 at 8:03 AM
	Edge Therapeutics Announces Additional Pharmacokinetic Data Supporting the Potential Clinical and Health Economic Impact of EG-1962 in Aneurysmal Subarachnoid Hemorrhage (NASDAQ:EDGE) www.publicnow.com - September 6 at 4:39 PM
	Horizon Discovery inks new collaboration (NASDAQ:EDGE) www.proactiveinvestors.co.uk - September 6 at 9:37 AM
	5 Top NASDAQ Biotech Stocks: Cynapsus Therapeutics Soars on Acquisition - Investing News Network (press release) (registration) (blog) (NASDAQ:EDGE) investingnews.com - September 5 at 4:28 PM
	Cynata and FUJIFILM Sign Non-binding Development and Commercialisation Term Sheet - PR Newswire (press release) (NASDAQ:EDGE) www.prnewswire.com - September 5 at 4:28 PM
	Stock Struggling for the Quarter: Edge Therapeutics, Inc. (:EDGE) - Post News (NASDAQ:EDGE) www.kentuckypostnews.com - September 4 at 9:14 AM
	Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Puts Investors On The Edge - Scibility Media (NASDAQ:EDGE) scibilitymedia.com - September 2 at 4:41 PM
	Edge Therapeutics to Present Additional Data from Phase 1/2 NEWTON Study of EG-1962 at Two Scientific Conferences in September (NASDAQ:EDGE) finance.yahoo.com - September 1 at 4:41 PM
	Trillium Therapeutics : Introduces Industry Postdoctoral Fellowship Program (NASDAQ:EDGE) www.4-traders.com - August 30 at 4:49 PM
	Biotech one step closer to bowel disease treatment (NASDAQ:EDGE) scienceblog.com - August 22 at 4:49 PM
	The Green Rush: Searching for (High) Yields (NASDAQ:EDGE) wire.kapitall.com - August 22 at 4:49 PM
	Edge Therapeutics, Inc. (Nasdaq: EDGE) to Ring The Nasdaq Stock ... - GlobeNewswire (press release) (NASDAQ:EDGE) globenewswire.com - August 20 at 8:12 AM
	Edge Therapeutics, Inc. (Nasdaq: EDGE) to Ring The Nasdaq Stock Market Closing Bell - EIN News (press release) (NASDAQ:EDGE) www.einnews.com - August 19 at 3:52 PM
	Edge Therapeutics, Inc. (Nasdaq: EDGE) to Ring The Nasdaq Stock Market Closing Bell (NASDAQ:EDGE) www.publicnow.com - August 19 at 3:52 PM
	Digital therapeutics market worth 457.9 million USD by 2021 according to new research report (NASDAQ:EDGE) www.whatech.com - August 19 at 7:44 AM
	Shares Moving Lower Over the Past Month Edge Therapeutics, Inc. (:EDGE) - Post News (NASDAQ:EDGE) www.kentuckypostnews.com - August 18 at 7:26 AM
	EDGE THERAPEUTICS, INC. Financials (NASDAQ:EDGE) finance.yahoo.com - August 11 at 4:55 PM
	Edge Therapeutics, Inc. (NASDAQ:EDGE) Trading Unchanged - Insider Trading Activity - Finance Daily (NASDAQ:EDGE) www.fidaily.com - August 9 at 8:59 PM
	Edge Therapeutics Inc.: Edge Therapeutics Reports Second Quarter Financial Results and Recent Highlights (NASDAQ:EDGE) www.twst.com - August 4 at 4:58 PM
	Edited Transcript of EDGE earnings conference call or presentation 3-Aug-16 12:30pm GMT (NASDAQ:EDGE) finance.yahoo.com - August 4 at 7:53 AM
	BRIEF-Edge Therapeutics reports Q2 loss per share $0.33 - Reuters (NASDAQ:EDGE) www.reuters.com - August 3 at 10:24 PM
	Edge Therapeutics' (EDGE) CEO Brian Leuthner on Q2 2016 ... - Seeking Alpha (NASDAQ:EDGE) seekingalpha.com - August 3 at 10:24 PM
	Edge Therapeutics Inc Earnings Call (Q2 2016) (NASDAQ:EDGE) biz.yahoo.com - August 3 at 4:54 PM
	Edge Therapeutics' (EDGE) CEO Brian Leuthner on Q2 2016 Results - Earnings Call Transcript (NASDAQ:EDGE) seekingalpha.com - August 3 at 4:54 PM
	Edge Therapeutics Reports Second Quarter Financial Results and Recent Highlights (NASDAQ:EDGE) finance.yahoo.com - August 3 at 4:54 PM
	EDGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E (NASDAQ:EDGE) biz.yahoo.com - August 3 at 4:54 PM
	Edge Therapeutics Reports Second Quarter Financial Results and Recent Highlights - GlobeNewswire (press release) (NASDAQ:EDGE) globenewswire.com - August 3 at 7:35 AM
	Edge Therapeutics reports 2Q loss (NASDAQ:EDGE) sg.finance.yahoo.com - August 3 at 7:35 AM
	Q2 2016 Edge Therapeutics Inc Earnings Release - Before Market Open (NASDAQ:EDGE) biz.yahoo.com - August 3 at 7:35 AM
	Edge Therapeutics Inc Earnings Call scheduled for 8:30 am ET today (NASDAQ:EDGE) biz.yahoo.com - August 3 at 7:35 AM
	EDGE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia (NASDAQ:EDGE) biz.yahoo.com - August 2 at 4:55 PM
	BRIEF-Edge Therapeutics says closing a dual-tranche term loan with Hercules Capital - Reuters (NASDAQ:EDGE) www.reuters.com - August 2 at 9:34 AM
	Edge Therapeutics Announces Closing of $20 Million Debt Facility ... - GlobeNewswire (press release) (NASDAQ:EDGE) globenewswire.com - August 2 at 9:34 AM
	6:36 am Edge Therapeutics closes a $20 million dual-tranche term loan (NASDAQ:EDGE) finance.yahoo.com - August 2 at 9:34 AM